MissionIR Small-Cap Investor Blog: August 2015

Monday, August 31, 2015

EquityFeed Hailed as the Most Actionable Stock Discovery Platform Ever Built

How do you find and profit from the best stock trading opportunities each day? If your daily routine includes checking your stocks and scouring the web for high quality plays, then you’re not alone. In the past, locating the best investment opportunities was a timely, inefficient process, but those days are over thanks to EquityFeed.

EquityFeed is a real-time, actionable information platform specially designed to suit the needs of individual stock traders – including those of you trading from home. The platform’s ultra-powerful scanning functionality is ideal for traders who don’t mind gaining an unfair advantage in their stock hunting efforts. Seriously, it’s like shooting fish in a barrel!

Start by creating customized and incredibly powerful filters for your specific intraday trading routine. With these filters in place, the stocks you want to know about will come to you instead of you looking for them. The EquityFeed filter builder provides the options needed to fully personalize your experience while promoting optimal results.

One of the most exciting features of the EquityFeed platform is its complete alert management interface. If a stock that may be in your wheelhouse demonstrates patterns and technical events worthy of your attention, EquityFeed will let you know. In other words, you’ll be ready to capitalize on stocks that are making new highs, new lows, breaking price averages, breaking volume averages, moving large block trades and much more without the need to spend your valuable time searching for easy-to-miss action.

Once you’ve got a stock in your sights, EquityFeed’s proprietary decision support mechanic is the perfect tool for helping you pull the trigger with confidence. The chart montage is your go-to source for more in-depth information after an interesting stock has been identified. Featuring a clean and compact design, this window will deliver all the real-time data needed to help ensure that the stock on your mind is a worthwhile investment.

If, for some reason, you’re not ready to move on a particular stock, you’ll be able to keep it within reach through the use of EquityFeed’s intuitive limit alerts feature. Just add the stock, and you’ll be alerted when news is released or a specified threshold, such as price, volume, bid, ask or change, is crossed. With EquityFeed, you’ll be able to go on with your business without taking your finger off the pulse of the market.

All of these features, along with the option to seamlessly integrate with many of the country’s most popular brokers for instant trade execution and unrivalled speed, combine to make EquityFeed a truly revolutionary approach to the stock discovery platform. If you’re ready to make your daily routine more efficient while simultaneously promoting bigger earnings, you’ll want to check out the free 14-day trial.

For more information, visit www.dtn.fm/equityfeed-trial

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Erin Energy Corp. (ERN) Building Shareholder Value through Exploration and Development of Assets in Sub-Saharan Africa

Erin Energy is an independent oil and gas exploration and production company focused on energy resources in sub-Saharan Africa. The company’s asset portfolio includes nine licenses across four countries covering an area of approximately 16,600 square miles, including current production and exploration projects offshore Nigeria, as well as exploration licenses offshore Ghana and the Gambia and both offshore and onshore Kenya. By expertly managing its investments and on-going operations, Erin Energy is able to combat current market conditions by limiting capital exposure while maintaining economic efficiency in its operations and maximizing investment value.

In recent months, the company has made tremendous progress in advancing its exploration and development programs. On its project in Nigeria, Erin Energy successfully tied in two wells, Oyo-7 and Oyo-8, in the Oyo field. This achievement preceded the commencement of production in May. In total, the two wells accounted for production of more than 450,000 barrels of oil in the second quarter of 2015, giving the company considerable momentum as it looks to increase its production capacity moving forward.

“Bringing the Oyo-7 and Oyo-8 wells on production were significant milestones in the company’s history,” Kase Lawal, chairman and chief executive officer of Erin Energy, stated in a news release. “Growth is at the center of Erin Energy and this achievement is just the beginning for us.”

The company’s recent progress in the development of its Nigeria asset has been accompanied by equally noteworthy progress on other assets in its portfolio. On August 21, Erin Energy announced that it had received approval from the government of Kenya to enter the first additional exploration period on its onshore blocks, L1B and L16. According to the terms of this approval, the company will be required to acquire, process and interpret approximately 116 square miles of 3D seismic data and drill one exploration well on each block within the next two years.

“We are very pleased to begin the next phase of exploration in Kenya,” continued Lawal. “Our team is greatly encouraged by the results of our exploration efforts thus far, and excited by the significant hydrocarbon potential we see on the blocks.”

Since the start of oil production, the company’s wells have consistently outperformed pre-drill projections. As of August 1, the combined production rate of Oyo-7 and Oyo-8 was approximately 13,100 barrels of oil per day, giving Erin Energy a strong channel with which to generate revenue while continuing to expand its operations. Look for the company to build on these strong results as it progresses exploration efforts across its sizable asset portfolio in the months to come.

For more information, visit www.erinenergy.com

Skyline Medical, Inc. (SKLN) (SKLNU) Providing a Safer Approach to Surgical Waste Handling with Innovative STREAMWAY® System

Skyline Medical, Inc. (NASDAQ: SKLN, SKLNU) is a medical device company engaged in the production and commercialization of an innovative, environmentally-friendly tool targeted at improving the safety of one of the most dangerous jobs in the medical field. The company’s proprietary STREAMWAY® system is a cost-effective, canister-free platform that eliminates the frequent and potentially hazardous interruptions commonly associated with surgical waste handling. Utilizing a direct-to-drain installation, Skyline’s technology greatly reduces the risk of hospital staff being exposed to biohazard fluids while simultaneously promoting improved patient-focused care and significant time savings.

The immense benefits of the STREAMWAY system have helped the company make considerable strides toward achieving sustainable market growth in recent years. Originally released in 2009, Skyline has sold 89 units to date, and the company expects this figure to rapidly expand as it looks to bolster sales and production efforts. As new hospitals continue to approve the use of the groundbreaking STREAMWAY system for additional applications, Skyline expects to significantly improve its financial results.

In the first quarter of 2015, Skyline successfully leveraged the marketability of its innovative system to promote strong financial growth. In addition to selling and shipping five STREAMWAY units, the company realized a 115 percent year-over-year increase in total revenues, recording $151,274 for the period. Likewise, Skyline’s net loss and total expenses were reduced by more than $1.3 million during the quarter, as compared to the previous year.

“Our sales increased year-over-year as we continue to make sales to large and diverse medical centers across a broader geographical area,” Josh Kornberg, chief executive officer of Skyline, stated in a news release. “We are optimistic about our business opportunities as we execute on our sales strategy.”

In recent weeks, Skyline has turned its attention toward increasing its market visibility and securing the capital necessary to continue progressing with its strategic business plan. The company recently announced a public offering that’s expected to raise approximately $15 million to fund its ongoing sales efforts while allowing Skyline to increase its product inventory in the future. These actions will be a key part of Skyline’s progress toward market growth, particularly as the company targets achieving profitability as early as next year.

For prospective shareholders, the increasingly widespread adoption of Skyline’s proprietary STREAMWAY technology could provide a platform for ongoing growth. Look for the company to benefit from an improved cash position following the completion of its upcoming public offering as it continues to build upon it recent progress in the future.

For more information, visit www.skylinemedical.com

Friday, August 28, 2015

Catalyst Pharmaceuticals, Inc. (CPRX) Rapidly Approaching Commercialization of Firdapse®

Catalyst Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for people with rare debilitating diseases. The company’s lead product candidate, Firdapse®, recently completed a pivotal phase III clinical trial for the treatment of Lambert-Eaton myasthenic symdrome (LEMS), a rare neuromuscular, autoimmune disorder that afflicts about 3,000 people in the United States. Catalyst took a significant step toward the eventual commercialization of its innovative candidate when it initiated submission of a rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) earlier this year. The company anticipates completing this submission during the fourth quarter, putting it on schedule for approval in the first half of 2016.

“[W]e have been working diligently to advance regulatory and commercial affairs and are pleased with the initiation of our rolling NDA submission to the FDA for Firdapse,” Patrick J. McEnany, chief executive officer of Catalyst, stated in a news release. “Additionally, we are on schedule with our key commercial strategic imperatives to support the successful launch of Firdapse.”

Catalyst’s development pipeline also includes CPP-115, which is being studied for the treatment of infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette’s disease. CPP-115 has been granted U.S. orphan drug designation by the FDA for the treatment of infantile spasms, making it eligible for a host of incentives designed to limit the costs associated with future development efforts.

In February, the company completed an offering of common stock that raised net proceeds of approximately $34.9 million to help fund its promising development programs. As of June 30, Catalyst reported cash and cash equivalents of $67.4 million with no outstanding debt. These considerable resources are expected to fund the company’s ongoing operations through the anticipated approval and subsequent product launch of Firdapse in 2016.

As it approaches the commercial launch of Firdapse, Catalyst is in a favorable position to promote strong financial growth. Look for the company to benefit from the operational flexibility afforded by its strong balance sheet as it focuses on making significant progress with the ongoing development of its product pipeline.

For more information, visit www.catalystpharma.com

Thursday, August 27, 2015

International Stem Cell Corp. (ISCO): A Double Threat with Cutting-Edge, Ethically Derived Stem Cell Therapies & Commercial-Scale Biobanking

On the cusp of milestone TGA (Therapeutic Goods Administration) authorization in Australia to start clinical trials in its breakthrough Parkinson’s disease (PD) treatment using human parthenogenetic neural stem cells (hpNSCs), International Stem Cell Corp. (OTCQB: ISCO) was proud to show markets recently that the company has achieved a point of maturity where it is also driving home steadily increasing revenues. The release of the company’s Q2 2015 data also showed record net income for the quarter, with outlays decreasing due to having successfully wrapped on a number of important preclinical studies, even as revenues increased 14 percent year over year, and profit margins held steady at around 72 percent.

The company’s increasingly lucrative biomedical business and consistently profitable regenerative skin care offerings, administrated respectively via ISCO’s wholly-owned Lifeline Cell Technology and Lifeline Skin Care subsidiaries, continue to materially backstop the ongoing development of an exciting therapeutic pipeline based on proprietary human parthenogenetic stem cell (hpSC) technology which is efficient, perfect for commercial scale volumes, and also completely ethical. ISCO’s parthenogenesis technology employs a unique chemical stimulation technique for triggering unfertilized donor human eggs to create pluripotent cells that can then be differentiated through proprietary activation into numerous types of cells. From the aforementioned hpNSCs, which are increasingly seen via the company’s trial work as a paradigm shift approach when it comes to treating neurological system conditions like PD and even ischemic stroke. To liver and eye cells that can be used to effectively treat degenerative diseases affecting those tissue systems, such as metabolic liver disease and macular degeneration.

Just looking at the company’s application of hpNSCs in PD, we see a fundamentally new approach to therapy using transplanted stem cells, which could actually solve the underlying problems that give rise to such conditions, rather than just attempting to ameliorate the condition as with many other therapies, including the current standards of care. In PD, where injected hpNSCs actively differentiate into both dopaminergic neurons, as well as express brain-protecting neurotrophic factors, and thus directly address the two primary causes of debilitation, this approach shows its monumental superiority to other approaches by simultaneously replacing dead neurons and protecting any survivors. This kind of therapeutic solution constitutes an end-run on PD, and potentially many other diseases/disorders via a completely ethical, high-volume stem cell production technology, and it could make ISCO into one of the now $27 billion plus global stem cell market’s heaviest hitters.

Recent projections by Transparency Market Research indicate that the global stem cell market is just getting warmed up too. With around 24 percent CAGR seen occurring through 2018 and valuations the following year of as much as $119 billion or more, this highly fragmented market is primed for explosive growth. Something which is especially true for real innovators like ISCO, given that pluripotent stem cells are also seen as rapidly eclipsing the core adult stem cell type that currently has around 80 percent of the market share.

Perhaps even more importantly, the company’s UniStemCell bank, which is effectively the life science industry’s first commercial-scale aggregation of histocompatible, non-embryonic human stem cells, is ideally positioned to benefit from the continued upswing in the sector. Providing a growing logistical footprint of high-quality material for research purposes, as well as commercial applications. Moreover, ISCO has established a solid presence already here in the U.S., which is the epicenter of global activity for the stem cell industry due to federal government support for the sector. As the biobanking market expands further into Europe and other global markets, the company will benefit from first-mover advantages.

To take a closer look, visit www.internationalstemcell.com

ENGlobal Corp. (ENG) Expands Management Team

ENGlobal, a leading provider of automation and engineering services, announced this morning that it has added two key professionals to its management team in newly created positions. The decision to expand its leadership team was made to support the company’s strategic commitment to further strengthen its midstream project execution and automation engineering businesses.

John Offutt will be serving as General Manager — Midstream Projects, with responsibility of the company’s Tulsa and Houston midstream operations. Offutt brings his knowledge and experience in managing all phases of large transportation-related projects, with the majority of his 30-year career having been with a major midstream operating company.

In his most recent assignment, Offutt managed a $700 million capital budget including 280 miles of pipeline and associated facilities. Offutt has directed teams of project managers, engineers, construction managers and support functions, being responsible for the successful execution of a lengthy list of both large and small diameter pipeline projects.

Robert Sammons will be serving as general manager — Automation Engineering. In his role, Sammons will be expanding ENGlobal’s automation capabilities, in addition to supervising several of the company’s existing projects and technologies.

Sammons has gained extensive automation experience during his 25 year career, with senior level responsibilities focused on both business development and operations. Most recently he has been active in his own business providing Process Hazard Analysis and Burner Management Safety systems to midstream processing, refining and petrochemical clients.

“ENGlobal is privileged to include both John and Robert as senior professionals and members of the ENGlobal Team,” William A. Coskey, P.E., ENGlobal’s chairman and chief executive officer, stated in the news release. “Our intent in the current market is to remain dynamic and proactive as a company, building upon our many project execution skills and thereby demonstrating our continuous commitment to better serve our valued clients.”

For more information, visit www.ENGlobal.com

Wednesday, August 26, 2015

ENGlobal Corporation (ENG) Leaning on Experience of Leadership Team to Promote Profitability Despite Slumping Energy Prices

In recent weeks, ENGlobal Corporation (NASDAQ: ENG) has provided prospective shareholders with a glimpse into its considerable growth potential. Despite slumping energy prices, the company demonstrated its versatility in the second quarter of 2015 by recording its sixth straight quarter of profitability. This accomplishment is validation of ENGlobal’s recent efforts to streamline its operations while continuing to promote market growth. In particular, the company has maintained strict levels of control over overhead costs in its two operating segments – engineering, procurement and construction management (EPCM) and automation – while continuing to closely monitor the spending of its clients.

“ENGlobal’s profit margins remain respectable given the current environment, and our available capital has improved over the last year,” Mark Hess, chief financial officer of ENGlobal, stated in a news release earlier this month. “The Company continues to maintain a healthy cash balance and working capital of $25.4 million, and we have no borrowings under our current credit facility.”

In the company’s quarterly report, it highlighted the high level of proposal activity it’s seen in recent months, which could provide an indication as to its market potential moving forward. By minimizing costs, ENGlobal has ensured that its services have remained very competitive while it continues to focus on marketing centered on its differentiated products and services. Additionally, the company has been vocal about the possibility of capitalizing on current energy market conditions by purchasing proprietary or differentiated technologies or processes in order to increase the marketability of its unique portfolio in the future.

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” William Coskey, P.E., chairman and chief executive officer of ENGlobal, stated. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

With a strong balance sheet in place, ENGlobal will lean on the immense industry experience of its management team as it looks to adapt to current market conditions. In total, the company’s leadership team brings well over a century of combined experience to the table. William Coskey, the company’s president and CEO, has served in his current position since 2012, and he has been with ENGlobal in some capacity since its founding in 1985. This management stability should provide the company with an advantage as it looks to navigate the current energy market.

The company’s ability to remain profitable despite slumping oil and gas prices is a positive indication of its potential in the months to come. Look for ENGlobal to continue limiting unnecessary costs while leveraging the flexibility provided by its strong cash balance in order to explore strategic acquisition opportunities in the months to come.

For more information, visit www.englobal.com

Foundation HealthCare, Inc. (FDNH) Leading the Way in Value-Based Healthcare Market with Unrelenting Focus on Patient Care

Foundation HealthCare, Inc. (OTCQB: FDNH) owns and operates surgical hospitals that provide both general and specialty surgeries – including orthopedics, neurosurgery, pain management, podiatry, gynecology, optometry and gastroenterology – as well as a collection of ancillary hospital-based services that helps set the Foundation HealthCare specialty hospital environment apart from the competition. Additionally, Foundation HealthCare is an industry-leading ambulatory surgery center (ASC) management and development company offering turnkey management and development solutions for its physician partners. Through these operations, the company is focused on creating an outstanding patient experience while maximizing partner and shareholder value.

“Patient care is our number one priority at Foundation HealthCare and a key differentiator in our business model,” Stanton Nelson, chief executive officer of Foundation, stated in a news release. “Our physician partners and our clinical teams continue to perform at a high level which is why we believe our patient satisfaction scores are some of the highest in the country.”

In the second quarter of 2015, the company successfully translated its high patient satisfaction scores into strong financial results. Foundation achieved a 44 percent year-over-year increase in net revenues for the period, recording $31.9 million, while its adjusted EBITDA rose by a massive 246 percent to $3.6 million. The company also took significant steps toward ensuring future growth through the sale of its minority interest in an underperforming hospital in Sherman, Texas, for a gain of $6.3 million and the negotiation of a $20 million line of credit to aid in the pursuit of viable acquisition targets.

“The core of Foundation’s growth strategy is to expand services at our majority-owned hospitals and acquire more of these hospitals,” continued Nelson. “Our $20 million acquisition line of credit… combined with our continued growth positions us well to aggressively pursue opportunities in new geographic markets.”

The company’s current portfolio of facilities and affiliates includes two majority-owned surgical hospitals located in San Antonio and El Paso, Texas, as well as minority interests in one hospital in Edmond, Oklahoma, and eight ASCs located across five states. Foundation also maintains an interest in one hospital outpatient department through its investment in the Edmond hospital, and the company has a management contract with one ASC in Louisiana in which it has no ownership interest.

As the healthcare industry continues to shift toward value-based care options, this diverse portfolio of properties should provide Foundation with a platform to realize sustained financial growth moving forward. Look for the company to leverage the added flexibility afforded by its recently negotiated line of credit in order to capitalize on this market shift while promoting strong returns for the foreseeable future.

For more information, visit www.fdnh.com

ATRM Holdings, Inc. (ATRM) Records Strong Growth in Single Family Home Sales

ATRM Holdings, Inc. (NASDAQ: ATRM), through wholly-owned subsidiaries KBS Builders, Inc. and Maine Modular Haulers, Inc., manufactures, sells and distributes modular housing units for commercial and residential applications. The company’s offerings include single family homes; multi-family housing units, such as apartment buildings, condominiums, townhouses and dormitories; and commercial structures, including hospitals, office buildings and other constructions. ATRM utilizes a combination of direct sales staff and independent dealers and contractors in order to market and sell its products.

Since acquiring KBS Builders in April 2014, ATRM has turned much of its focus toward strengthening its balance sheet and implementing organizational, process and contractual improvements designed to boost commercial project performance. In June, the company took a significant step toward achieving this goal when it announced a settlement agreement that greatly decreased outstanding debt related to the KBS acquisition. In addition to reducing the principal debt from $5.5 million to $2.5 million, ATRM successfully restructured the payments in order to facilitate financial growth in the months to come.

“This settlement agreement is a very favorable outcome for the company,” Dan Koch, president and chief executive officer of ATRM, stated in a news release. “Reducing our debt and restructuring the payments over 25 months will allow us to better utilize cash flow for additional operating improvements, gaining efficiencies and ultimately growing our business.”

In the second quarter of 2015, the company also made considerable progress in single family home sales, recording a 26 percent year-over-year increase for the period. Despite a sharp decline in commercial sales, ATRM also made significant headway toward profitability by decreasing its net loss from the previous year by $4.5 million. This was achieved as a result of substantially decreased costs and expenses for the quarter, as well as the implementation of a strategic shift away from site-related expenses, which have historically resulted in losses for the company.

“The problems with several commercial projects that were under contract at the time of the acquisition have adversely impacted our gross margins, including our margins in Q2 2015, but have essentially been eradicated,” continued Koch. “We expect that our commercial projects will be significantly more profitable in the future due to the changes we have made. We believe we are positioned to achieve sales in the second half of 2015 of at least $16 million with continued improvement in gross margins and operating results.”

For prospective shareholders, ATRM’s progress toward streamlining its operations following the acquisition of KBS Builders is a promising indication of the company’s potential moving forward. Look for ATRM to bolster its current cash position through a planned offering of its common stock in the coming weeks, effectively setting the stage for a strengthened balance sheet and sustainable returns in the growing modular construction market.

For more information, visit www.atrmholdings.com

Tuesday, August 25, 2015

Harte Hanks, Inc. (HHS) Going beyond Brand Engagement with Innovative Approach to Marketing

Harte Hanks, Inc. (NYSE: HHS) offers a full spectrum of multichannel marketing services designed to turn browsers into buyers and customers into dedicated brand advocates. The company’s innovative marketing approach utilizes a three-step process that helps clients go beyond brand engagement to create campaigns that develop memorable experiences in the hearts and minds of customers. Through a unique combination of data management and creative development, Harte Hanks has delivered impactful results for some of the world’s best-known brands – including Sony (NYSE: SNE), Kohl’s (NYSE: KSS), Adobe (NASDAQ:ADBE), Panasonic (OTC:PCRFY) and U.S. Airways of American Airlines Group (NASDAQ:AAL).

In the second quarter of 2015, the company leveraged the marketability of its platform to record promising financial results. Despite realizing a mild drop in year-over-year customer interaction revenue as a result of the recent sale of its business-to-business (B2B) research affiliates, Harte Hanks achieved strong growth in both its financial and healthcare verticals following the addition of new clients. Moving forward, the company will look to build upon its solid foundation in the marketing industry through the development of market leading products and tools that better connect clients with their customers and the continued integration of its recent acquisition, 3Q Digital.

“Our goal remains to deliver consistent revenue growth,” Doug Shepard, chief executive officer of Harte Hanks, stated in a news release. “During the first half of the year, we enhanced our capabilities by completing our first acquisition in five years and better focused our product offerings by selling our B2B research businesses, which were no longer relevant to our strategy.”

In an effort to remain on the forefront of the evolving data marketplace, Harte Hanks recently announced the evolution of its big data strategy, adopting Apache Hadoop with the MapR platform. This move is expected to enhance the performance, scalability and flexibility of the company’s current solutions, enabling clients to more easily and quickly migrate, analyze and store massive quantities of data. By providing the means for deeper analysis and flexibility of stored data and increasing database capacity and performance, Harte Hanks expects its collaboration with MapR to play a vital role in the company’s efforts to create smarter customer interactions through more personalized and relevant content delivery.

As Harte Hanks continues to make progress toward streamlining its multichannel marketing strategy, it is in a favorable position to improve its profitability in the future. For prospective shareholders, the flexibility offered by the company’s strong cash position following the sale of its B2B research affiliates earlier in the year could provide an opportunity for Harte Hanks to promote sustainable returns in the months to come.

For more information, visit www.hartehanks.com

Condor Hospitality Trust, Inc. (CDOR) Utilizing Accelerated Strategy to Reinvest in Newer, Premium-Branded Hotels

Condor Hospitality Trust, Inc. (NASDAQ: CDOR), formerly Supertel Hospitality, Inc., is a real estate investment trust (REIT) specializing in the select-service segment of the lodging industry. The company currently owns 46 hotels across the country operated by some of the hotel industry’s most well-regarded brand families – including Hilton (NYSE:HLT), Choice Hotels International (NYSE:CHH) and Wyndham (NYSE:WYN). In recent months, Condor has utilized an accelerated strategy aimed at transitioning its asset portfolio away from economy properties in the direction of newer, premium-branded upper midscale and upscale extended-stay hotels located primarily in the nation’s top metropolitan areas.

“Condor has an active acquisition pipeline, and we anticipate continuing the accelerated pace of capital recycling which we project will further strengthen our balance sheet through debt reduction and increasing liquidity, thereby enhancing the strategy underway to significantly grow the company through acquiring a much higher quality portfolio with the objective of increasing shareholder value,” Bill Blackham, chief executive officer of Condor, stated in a news release.

In July, Condor gave prospective shareholders a preview of this updated strategy when it announced the sale of two hotels in Alexandria, Virginia. Through this $19 million transaction, the company was able to retire $8.3 million in debt while applying the net proceeds to future acquisition efforts. As of its latest update, Condor was marketing 15 hotels for sale, which were expected to generate approximately $12.4 million in net proceeds after associated debt repayments.

The company has also made considerable progress toward bolstering its portfolio in recent weeks. Last month, Condor announced the signing of an agreement to acquire three properties in San Antonio, Atlanta and Jacksonville that fall squarely into its updated business strategy. These hotels, which are currently branded under the Marriott (NYSE:MAR) and InterContinental Hotels (NYSE:IHG) brand families, provide a “window into the company’s portfolio of the future,” according to Blackham.

Despite its aggressive transition efforts, Condor has continued to post strong financial results in recent months. In the second quarter of 2015, the company recorded $16.4 million in revenue from continuing operations, realizing a mild year-over-year increase. These results were driven by Condor’s increased revenue per available room, which rose by 4.3 percent from the previous year. This consistent performance should aid in the company’s continued efforts to transform its current property portfolio in the months to come.

For prospective shareholders, the company’s recent progress toward transitioning its property portfolio makes it an intriguing investment opportunity moving forward. Look for Condor to make significant strides toward achieving increased shareholder value as it works to strategically position itself in some of the country’s most lucrative hospitality markets.

For more information, visit www.condorhospitality.com

Net Element, Inc. (NETE) Enters Kazakhstan Market through Strategic Partnership Agreements

Net Element (NASDAQ:NETE), a provider of global mobile payment technology solutions and value-added transactional services, has completed partnership agreements with Kcell JSC, and Beeline, a wholly owned subsidiary of VimpelCom, Ltd (NASDAQ:VIP).

Per the agreements, Kcell and Beeline will use Net Element’s mobile payment platform, TOT Money, to facilitate mobile payments for its subscribers; the deals also position Net Element with strong anchors in a rapidly growing marketplace.

Both Kcell and Beeline have leading positions in Kazakhstan, the world’s ninth biggest country. As the largest mobile operator in the region, Kcell has 10.76 million customers, while Beeline, ranked second, has 9.8 million customers.

Launching TOT Money in Kazakhstan expands on the recent launch of PayOnline’s online and mobile in-app payment services in partnership with Kazkommertsbank (“KAZKOM”), the largest private bank in Kazakhstan and one of the largest banks in Central Asia.

“By signing Kcell and Beeline in Kazakhstan, Net Element has solidified partnerships to provide mobile payment services for the largest mobile operators in the region. This is an important part of Net Element’s strategy to capitalize on Kazakhstan’s booming mobile marketplace and to position TOT Money as a leading mobile payments provider,” Oleg Firer, CEO of Net Element, stated in the news release.

For more information visit www.netelement.com

Monday, August 24, 2015

Moxian, Inc. (MOXC) Promoting Industry Growth with Innovative Online to Merchant Marketing Platform

Moxian, Inc. (OTCQB: MOXC) is a provider of social marketing and promotion platforms to merchants who desire to promote their businesses through online social media. By facilitating the study of consumer behavior through an extensive database of user activities, the company allows its clients to run advertising campaigns and promotions aimed at their specific target customers in potentially lucrative markets around the globe. Moving forward, Moxian aims to become a world leader in the sphere of online to merchant (O2M) marketing by effectively driving mobile users to online and offline retail merchants and rapidly accelerating its clients’ business growth.

Developed in Shenzhen, China, the Moxian platform integrates social and media features, combining entertainment and business into a valuable marketing tool. With innovative tools such as the company’s proprietary Social Customer Relationship Management system – which tracks important data on visitors – Moxian allows consumers and businesses to connect and interact with one another online while promoting improved interaction across a full range of sales channels. The company originally launched its marketing platform in Malaysia and China in June 2013 and July 2014, respectively.

In recent weeks, Moxian has turned its attention toward promoting sustainable market growth. In July, the company announced a three-year sponsorship of the prestigious China New Media Integrated Development Conference, which is organized by Xinhua News Agency, the official news agency of the People’s Republic of China. This sponsorship is expected to showcase Moxian as one of the world’s industry leaders in digital media. Additionally, the company announced its entry into a subscription agreement with Beijing Xinhua Huifeng Equity Investment Center last month that is expected to raise just under $8.2 million in capital to fund continued expansion efforts.

“The investment by Beijing Xinhua Huifeng Equity will allow us to continue to invest in Moxian’s growth, and, we believe, is a vote of confidence in the path we have set for the company,” Tan Meng Dong James, interim chief executive officer of Moxian, stated in a news release.

In the second quarter of 2015, Moxian leveraged the marketability of its innovative platform to record strong financial growth. The company’s gross revenues for the period rose 15 percent from the previous year, and this growth is expected to continue moving forward as Moxian benefits from the added flexibility provided by its recent capital infusion. For prospective shareholders, the company’s rapidly increasing brand visibility in the expansive Chinese advertising market could provide a platform for sustainable returns. Look for Moxian to lean on its innovative marketing technology in order to secure its position atop the O2M marketing industry in the years to come.

For more information, visit www.ir-moxian.com

Friday, August 21, 2015

ENGlobal Corp. (ENG) Demonstrates Versatility with Profitable Second Quarter Results

In the second quarter of 2015, ENGlobal Corp. (NASDAQ: ENG) recorded its sixth straight quarter of profitable results. In large part, these results were attributable to the consistent performance of the company’s engineering and construction segment, which accounted for over 61 percent of ENGlobal’s total revenue for the period. Despite the recent drop in oil and gas prices, which continue to hover near six-year lows, the segment’s performance was a mild improvement over the second quarter of 2014, further highlighting the effectiveness of the company’s current strategy aimed at expanding its market share and locating new clients and business opportunities.

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” William Coskey, P.E., chairman and chief executive officer of ENGlobal, stated in a news release. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

In addition to its profitable results in the second quarter, ENGlobal continues to maintain a favorable balance sheet, which should give the company an opportunity to capitalize on current market conditions through an aggressive pursuit of new client relationships and potential strategic acquisitions. As of its latest filings, ENGlobal reported a healthy cash balance and working capital of $25.4 million with no borrowings under its current credit facility.

Over the past three decades, ENGlobal has built a significant presence in a collection of energy markets through its unique commitment to innovation and cost-effective automation. With services ranging from feasibility studies and conceptual design to turnkey project responsibility, the company has established itself as a mainstay among the country’s top engineering firms. For this reason, ENGlobal has been ranked by Engineering News Record magazine as a Top 500 engineering design firm for more than 10 years.

ENGlobal’s strong results from its engineering and construction segment were supplemented by the performance of its automation segment. Although total revenue for the segment declined from the results of the previous year, the company was able to increase the segment’s gross profit margin by 7.4 percent in order to help it maintain profitability for the quarter.

For prospective shareholders, the company’s profitable results despite current market conditions continue to highlight the immense value of its experienced management team. Moving forward, look for ENGlobal to continue capitalizing on the opportunities presented by the current condition of the energy marketplace in order to promote strong results for the future.

For more information, visit www.englobal.com

Thursday, August 20, 2015

RestorGenex Corp. (RESX) Looks to Address Underserved Oncology Indications with Innovative Product Candidate

RestorGenex Corp. (OTCQX: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company’s lead product candidate, RES-529, is a novel PI3K/Akt/mTOR pathway inhibitor that has completed two phase I clinical trials for the treatment of age-related macular degeneration (AMD) and is in preclinical oncology development for the treatment of glioblastoma multiforme (GBM). RestorGenex has announced plans to initiate human clinical trials in GBM in 2016. Additionally, the company’s pipeline includes RES-440, a ‘soft’ anti-androgen compound for the treatment of acne vulgaris.

Through its ongoing development programs, RestorGenex is addressing a collection of underserved markets in the biopharmaceutical industry. According to industry data, the worldwide market for the treatment of GBM in 2013 was estimated at $1 billion, and that figure is expected to climb to $4.5 billion by 2020. Due to the modest effectiveness of currently available treatment options, this market performance could provide an opportunity for RestorGenex to achieve considerable financial growth upon commercialization of RES-529. The company’s innovative PI3K pathway inhibitor has also shown promise in a number of additional indications, which RestorGenex is currently evaluating for the purpose of creating safe and effective treatments.

“The scientific research and knowledge of RES-529 continues to expand, in particular for clinical oncology applications,” Stephen M. Simes, chief executive officer of RestorGenex, stated in a news release. “These new data help to validate our plans for future studies with RES-529, as well as suggest that its analogs could also be developed for oncology indications.”

Moving forward, RestorGenex will lean on the strength of its balance sheet as it progresses toward the commercialization of its promising development pipeline. As of June 30, 2015, the company reported cash and cash equivalents of approximately $16.5 million, which it expects to sufficiently fund its operations well into the second half of 2016. RestorGenex had no outstanding debt as of its latest financial filings.

For prospective shareholders, the potential marketability of RestorGenex’s development pipeline, particularly in oncology indications, could foreshadow an opportunity for the company to achieve considerable market growth in the future. Look for the company to continue benefitting from its favorable financial position as it advances its product candidates in the months to come.

For more information, visit www.restorgenex.com

International Stem Cell Corp. (ISCOD) Leading the Way in Emerging Field of Regenerative Medicine with Parthenogenetic Stem Cell Technology

International Stem Cell Corporation is a biotechnology company utilizing a proprietary new stem cell technology known as parthenogenesis to significantly advance the field of regenerative medicine. The company’s innovative technology uses unfertilized human eggs to create human pluripotent stem cells (hpSC) that can be immune-matched to millions of people around the globe. These stem cells are unique in that they provide the best characteristics of each of the remaining classes of cells without the need for the creation or destruction of a viable embryo.

The company’s business strategy features three unique channels for revenue generation within the biotechnology industry – including its core stem cell technology and related intellectual property, which encompasses 220 patents, applications and licenses associated with the development and manufacture of pluripotent cells, as well as its therapeutic research projects and promising development pipeline.

Lifeline Skin Care, the company’s wholly-owned subsidiary, is an industry leader in effective anti-aging stem cell skin care. Since being established in 2010, Lifeline has served as a growing source of vital financial support to fund ISCO’s ongoing medical research. In 2014, Lifeline accounted for more than $7 million in total revenue, which was primarily allocated to the advancement of the company’s promising development pipeline.

UniStemCell is the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. This cell bank gives the company a nearly inexhaustible source of stem cells that can be used to generate revenue in the medium term. As the company’s hpSC lines gain additional validation, they are expected to provide the company with royalty from sales of each successful hpSC-derived cellular therapeutic in the future.

In addition to the sale of its stem cells, ISCO is making noteworthy progress toward the continued advancement of its development pipeline. The company is currently engaged in pre-clinical development addressing a host of unmet medical needs. Parkinson’s disease, which affects an estimated one million people in the United States, represents ISCO’s leading development indication, with phase I/II clinical trials expected to begin in the coming months. Following the completion of initial studies, the company will seek out a suitable partner to assist with late-stage clinical development.

With its groundbreaking stem cell technology, ISCO is developing a significant presence within the expansive field of regenerative medicine. By successfully mitigating many of the limiting factors commonly associated with stem cell research – including auto-immune rejection and ethical debate surrounding the use of embryonic cells – the company is leveraging the marketability of its technology as a catalyst for continued growth.

Research indicates that the global regenerative medicine market is expected to grow at a CAGR of 12.2 percent through 2017, climbing to an estimated $24.7 billion by the end of the period. ISCO will look to capitalize on this market performance under the guidance of an executive management team with decades of experience in a collection of related scientific sectors.

For more information, visit www.internationalstemcell.com

Wednesday, August 19, 2015

Arotech Corp. (ARTX) Announces $6.7 Million Production Contract

Earlier today, Arotech reported a $6.7 task order from the Space and Naval Warfare Center (SPAWAR) Atlantic. The contract came through its North American Power System Division, which includes UEC Electronics.

The contract awarded is for the manufacture and integration of 12 Communication Emitter Sensing and Attacking System (CESAS) II Platform Integration Kits (PIK). The CESAS is the Marine Corps’ only high-power, ground-mobile electronic attack (EA) asset. The CESAS provides Commanders with the capability to detect, deny, and disrupt the communications of their enemy.

“UEC Electronics has been supporting the SPAWAR Intelligence group for more than 10 years and is pleased with the most recent contract award,” said Mark Matthews, CEO of UEC Electronics. “The DoD is focused on cost savings. Our automated manufacturing processes, coupled with our history of quality products and on-time delivery, make us an ideal provider for this type of mission critical system.”

Arotech received this award following the successful completion of a prototype test of the CESAS II PIK, which performed exceptionally well during U.S. Government-led performance and environmental testing.

Arotech expects to complete this production contract in the next 12 months. The government has an option which, if exercised, will result in a second year of support for the program.

Steven Esses, President and CEO of Arotech, commented, “The award of this contract is a testament to our team and performance of our product. We are excited about the initial opportunity and are optimistic that this award could lead to the procurement of additional units in the future.”

For more information, visit www.arotech.com

ENGlobal Corp. (ENG) Given Positive Writeup in Seeking Alpha

ENGlobal Corp., a specialty engineering services firm that focuses on oil and gas automation solutions, subsea control systems, and engineering and construction projects, was recently highlighted in a Seeking Alpha article, touching on how the company’s management team has turned the company back to profitability and staying profitable in spite of the current energy slump. The article indicates that the company is an undervalued micro-cap, given that the energy infrastructure industry is now in high demand, and that ENGlobal represents a high potential for a buyout.

In particular, the article (by Nicholas Bodnar) suggests that ENGlobal “is undervalued on a few different metrics”, giving investors “a great chance to get in at depressed levels”, with a significant long-term return potential. It points out the efforts made to minimize risk, and how ENGlobal management has been investing more into the automation side of the business, seen as a way of reducing the risks associated with profitability. It also points to the company’s prudent balance sheet, calling the chance of insolvency “almost non-existent”.

ENGlobal is about automation solutions and EPCM (Engineering, Procurement, Construction Management) projects, serving all levels of the energy industry, as well as pulp-and-paper, alternative energy, and government. The company offers services in engineering and construction, automation engineering/integration/design, and subsea controls and integration. Over the past two decades, they’ve developed a global reputation for designing state-of-the-art plant automation systems. The company’s driving vision is to become the preferred provider of innovative automation integration services and select EPCM projects to clients around the world.

Careful to differentiate themselves from companies where “quality” is more word than action, ENGlobal feels that they stake their reputation on delivering value-added products and services of the highest level, carefully following ISO-9001 guidelines. Establishing clear objectives at the outset of every project, the company emphasizes that it maintains open lines of communication throughout the duration of every project, strengthening working relationships to better understand and meet the client needs.

The Seeking Alpha article concludes that ENGlobal offers long-term investors an “enormous long-run upside”, with “a potential to make at least a 220% return in 3 years”.

For the complete article, go to http://seekingalpha.com/article/3431716-englobal-is-a-great-deep-value-micro-cap-energy-play.

For more information on the company, visit www.ENGlobal.com

Monday, August 17, 2015

TraderPower – Empowering Investors to Discover Exceptional Opportunities

TraderPower was established to empower investors with all the resources they need to make profitable trading decisions. Using the vast resources on the TraderPower website, the investment community can discover undervalued small-cap companies, learn how to properly analyze investment opportunities, and utilize free research tools for in-depth evaluation.

TraderPower’s #1 focus is on connecting investors with undervalued small-cap companies that are trading far below their true worth. With an estimated 15,000 publicly traded companies, it’s no surprise that these stocks exist. Of course once these neglected equities begin to get noticed, the climb to their fair valuation can be exceptionally profitable in a very short time.

Want to learn more? Visit www.TraderPower.com and discover your next profitable investment.

Friday, August 14, 2015

International Stem Cell Corp. (ISCOD) Preparing to Initiate Clinical Development for the Treatment of Parkinson’s Disease in Australia

International Stem Cell Corp. recently took a significant step toward expanding its clinical pipeline when it submitted preclinical data to the Australian Therapeutic Goods Administration (TGA) regarding its impending phase I/IIa clinical trial for the treatment of Parkinson’s disease. According to the submitted data, the company’s nine month study of 300 rodents resulted in no tumors being observed in any of the animal subjects, demonstrating the safety and efficacy of its human neural stem cells (hpNSCs), which were derived using ISCO’s proprietary parthenogenetic stem cell platform. The company predicts that this will be the final submittal required prior to the initiation of clinical studies.

“We expect that this study report will address the remaining safety elements necessary for regulatory approval,” Dr. Ruslan Semechkin, chief science officer of ISCO, stated in a news release. “Having provided this final submission we now look forward to receiving TGA authorization to begin our phase I/IIa clinical trial in Australia.”

If approved to begin clinical trials, ISCO will be in a strong strategic position to enter the Australian Parkinson’s disease treatment market in the future, which could provide the company with a substantial opportunity to achieve sustainable international growth. According to a report by Parkinson’s Queensland, approximately one in 350 Australians live with Parkinson’s disease, making it the country’s second most common neurodegenerative disorder. In 2011, the debilitating disease accounted for an estimated $480 million in national health system costs, further demonstrating the market potential of ISCO’s groundbreaking treatment option following regulatory approval.

ISCO’s proprietary approach to stem cell research, parthenogenesis, directly addresses many of the limiting factors typically associated with regenerative medicine. In particular, the company’s parthenogenetic homozygous stem cell line can be a source of therapeutic cells for hundreds of millions of individuals with minimal risk of immune rejection following transplantation. Additionally, since its cells are derived from unfertilized eggs, ISCO avoids many of the ethical issues associated with embryonic stem cells without sacrificing their transformative pluripotent qualities.

For prospective shareholders, the company’s strong progress toward expanding its market share in the global regenerative medicine industry could foreshadow an opportunity for sustainable returns in the months to come. Look for ISCO to build on this progress moving forward as it eagerly awaits TGA authorization to begin its pivotal clinical development program in the Australian market.

For more information, visit www.internationalstemcell.com

Comstock Resources, Inc. (CRK) Making Strong Developmental Progress Despite Slumping Commodity Prices

Comstock Resources is a growing independent energy company engaged in the acquisition, development, production and exploration of oil and natural gas properties. As of December 31, 2014, the company owned interests in nearly 1,600 producing wells with an estimated 620 BCFE in proven reserves. In recent months, the substantial decline of oil and natural gas prices has resulted in a considerable decline in revenues for the entire industry, with major players such as Exxon Mobil Corporation (NYSE: XOM) and Chevron Corporation (NYSE: CVX) reporting year-over-year earnings decreases of more than 50 percent for the first six months of 2015. However, Comstock’s strong production figures during the first half of the year – including approximately 1.96 million barrels of oil and 19.3 billion cubic feet of natural gas – continue to demonstrate the company’s immense growth potential when commodity prices begin to recover.

In 2014, Comstock’s Eagle Ford shale horizontal well drilling program in East Texas served as a driver for the company’s considerable production growth. In total, the company successfully increased its oil production figures by 86 percent, adding 5.1 million barrels of oil and 5 billion cubic feet of natural gas to its proven reserves. During the second quarter of 2015, Comstock prepared to build on this progress through the completion of four additional horizontal wells on the property, effectively increasing its production capacity ahead of forecast rises in oil and natural gas prices in the months to come.

In July, the company took steps toward securing the financial flexibility needed to continue developing its most promising properties. In particular, Comstock entered into a definitive purchase and sale agreement to sell its properties in and around Burleson County, Texas, for approximately $115 million. Upon closing, this transfer will provide the company with the fiscal means to fund additional drilling programs at its Eagle Ford property while maintaining the flexibility required to capitalize on additional strategic opportunities.

“This sale strengthens our balance sheet by providing us with an opportunity to further improve our liquidity during a period of low oil and natural gas prices,” M. Jay Allison, chief executive officer of Comstock, stated in a news release.

Despite less-than-favorable market conditions, Comstock has made strong progress in recent months toward preparing for future growth. Look for the company to continue focusing primarily on site development work moving forward, providing a strong platform upon which to capitalize on recovering commodity prices in the future.

For more information, visit www.crkfrisco.com

ENGlobal Corp. (ENG) Expertly Navigates Slumping Oil and Gas Markets to Record Sixth Straight Quarter of Profitability

While oil prices have hovered near six-year lows for the majority of 2015, ENGlobal Corporation (NASDAQ: ENG) has continued to leverage the considerable industry experience of its management team to promote strong financial results. Last week, the company demonstrated the versatility and marketability of its offerings when it announced that the second quarter of 2015 marked its sixth consecutive quarter of profitability.

“We are pleased to report today’s profitable results – which I’m proud to say represent six consecutive profitable quarters,” Mark Hess, chief financial officer of ENGlobal, stated in a news release. “ENGlobal’s profit margins remain respectable given the current environment, and our available capital has improved over the last year.”

In an effort to counteract the effects of slumping oil and gas prices, ENGlobal’s management expertly adjusted the margins of its engineering and construction operations in the second quarter. In addition to decreasing gross profit margin by 2.5 percent, as compared to the previous year, the company’s operating profit margin was reduced by 0.6 percent. These adjustments allowed ENGlobal to remain competitive in less-than-ideal market conditions, effectively promoting growth despite substantial industry limitations.

Following the release of its financial results for the second quarter, this strategy proved to be effective. For the period, ENGlobal achieved a mild year-over-year increase in total revenue for its engineering and construction segment, which serves a collection of energy sectors adversely affected by the recent fall in commodity prices. In an effort to capitalize on this progress, the company has recently turned its attention toward broadening its industry presence through the development of new partnerships and the exploration of potential acquisition candidates.

“ENGlobal’s response to the current energy marketplace has been to increase our efforts in developing new business,” stated William Coskey, P.E., chairman and chief executive officer of ENGlobal. “While we are excited about several new opportunities and client relationships that this internal process has produced, it also appears to be a great time to consider strategic acquisitions.”

According to the its latest financial report, the company has a healthy cash balance and working capital of approximately $25.4 million. Additionally, ENGlobal reports no borrowings under its current credit facility. The flexibility provided by this strong balance sheet will prove instrumental to the company’s growth efforts moving forward, particularly as related to any acquisition agreements that may be in the cards.

For prospective shareholders, ENGlobal’s financial performance despite slumping commodity prices is a promising indication of its market potential in the coming months. Look for the company to continue relying on the considerable expertise of its leadership team – which includes well over a century of combined industry experience – in order to continue successfully navigating prevailing market conditions and promoting sustained profitability for the foreseeable future.

For more information, visit www.englobal.com

Thursday, August 13, 2015

Glori Energy, Inc. (GLRI) Revitalizing Mature Oil Properties with Proprietary AERO™ Technology

Glori Energy is an energy technology and oil production company leveraging its proprietary AERO™ technology to increase the amount of oil that can be produced from conventional wells. In addition to using the technology on its own U.S. oil fields, the company is currently providing its innovative system as a service to exploration and production firms around the globe. To date, the AERO platform, which represents more than 60 years of successful research in the application of biotechnology to oil recovery, has accounted for the production of millions of barrels of otherwise unattainable oil.

In recent months, low oil prices have led to significant drops in earnings for some of the industry’s biggest players – including Exxon Mobil Corporation (NYSE: XOM) and Chevron Corporation (NYSE: CVX) – further demonstrating the importance of cost-effective production methods. However, according to industry reports, only about one-third of all oil discovered in a typical reservoir is recoverable using conventional techniques.

Glori’s AERO system addresses this inefficiency by stimulating the reservoir’s naturally-occurring microbes in order to create pockets of biomass. These pockets, which form in trapped oil deposits, force dynamic and continuous changes of water flow patterns during secondary oil recovery methods, effectively creating additional pathways for oil to reach the surface. When used during water injection, Glori’s AERO technology has been shown to increase incremental recovery by as much as 12 percent, making it the most cost-effective, successful enhanced oil recovery technology available on the market.

In July, Glori announced that it had commenced the nutrient injection phase of AERO implementation at its Coke Field project in Wood County, Texas, marking the company’s first significant deployment on one of its own oil fields. Moving forward, Glori will look to build on this progress through adherence to an aggressive growth strategy centering on the acquisition of mature producing oil properties with favorable characteristics for AERO implementation. In the second quarter of 2015, Glori utilized this strategy to acquire its newest project, Bonnie View Field in South Texas.

“Bonnie View has over 30 million barrels of oil remaining, with less than 40 percent recovery factor in an extremely high-quality reservoir,” Stuart Page, chief executive officer of Glori, stated in a news release. “This provides an attractive target for AERO, and we believe that we will be able to economically recover over six million of these barrels.”

For more information, visit www.glorienergy.com